Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids

Leukemia. 2020 Nov;34(11):3077-3081. doi: 10.1038/s41375-020-0790-4. Epub 2020 Mar 9.

Affiliations

¹ Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, 1650 Orleans St. Room 243, Baltimore, MD, 21231, USA.
² Cancer Research Institute, Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
³ IO Therapeutics, Santa Ana, CA, USA.
⁴ Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, 1650 Orleans St. Room 243, Baltimore, MD, 21231, USA. gghiaur1@jhmi.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Cancer-Associated Fibroblasts / drug effects
Cancer-Associated Fibroblasts / metabolism
Cytochrome P450 Family 26 / genetics*
Disease Models, Animal
Drug Resistance, Neoplasm / genetics*
Humans
Mice
Receptors, Retinoic Acid / agonists
Receptors, Retinoic Acid / chemistry
Receptors, Retinoic Acid / metabolism
Retinoids / pharmacology*
Tretinoin / pharmacology*
Tumor Microenvironment / drug effects
Tumor Microenvironment / genetics
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents
Receptors, Retinoic Acid
Retinoids
Tretinoin
Cytochrome P450 Family 26

Grants and funding